RESEARCH ARTICLE

View Article Online
View Journal | View Issue Cite this: *Med. Chem. Commun.*,
2019, 10, 616Received 8th February 2019,
Accepted 14th March 2019

DOI: 10.1039/c9md00085b

rsc.li/medchemcomm

Expansion of the structure–activity relationships of
BACE1 inhibitors by harnessing diverse building
blocks prepared using a unified synthetic approach†Joan Mayol-Llinàs, ^{ab} Shiao Chow ^{ab} and Adam Nelson *^{ab}

The structural diversity of β -site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors was expanded by harnessing diverse building blocks that had been prepared via a unified lead-oriented synthetic approach. It was shown that the lipophilic cyclohexylmethyl group within a known series of BACE1 inhibitors could be productively replaced with a range of alternative ring systems.

Introduction

The exploration of chemical space, whilst controlling molecular properties at each stage of discovery, is an intrinsic challenge in medicinal chemistry.¹ Historically, chemical space has been explored unevenly and unsystematically,² which has limited the scaffold diversity of exemplified medicinal chemistry space.³ Furthermore, discovery practices have driven medicinal chemists away from optimal property space, and have increased the focus on flatter and more lipophilic compounds.⁴ Molecular weight (MW), lipophilicity and molecular complexity tend to increase during lead optimisation.⁵ The challenge of controlling molecular properties in CNS discovery programmes is further heightened by the need to cross the blood–brain barrier.⁶ To assist discovery, a multi-parameter optimisation (MPO) system for scoring CNS drug-likeness⁷ has been developed that integrates scores for six key molecular properties.‡

Previously, we adapted⁸ the CNS Lead MPO scoring system⁷ to guide the development of a unified synthetic approach to diverse scaffolds that, on decoration, would provide high-quality starting points for CNS drug discovery.⁹ Here, we demonstrate that these building blocks may be harnessed to expand the structural diversity of inhibitors of the CNS target BACE1. BACE1 is an aspartic protease that is responsible for the formation of amyloid β by sequential

cleavage of amyloid precursor protein (APP).¹⁰ The amino-quinoline fragment **1**, which interacts with the two catalytic Asp residues, previously served as a starting point for fragment-based inhibitor discovery of BACE1 inhibitors.¹¹ Optimisation had initially involved the addition of an amide chain (to give **2**) bearing a lipophilic cyclohexylmethyl group. Successive addition of an *o*-tolyl group (to give **3**) and a methyl group (to give **4**) resulted, respectively, in ~ 900 - and 9-fold increases in activity (Fig. 1).

Results and discussion

Initially, we investigated the replacement of the lipophilic cyclohexylmethyl group in the inhibitor **2** with more highly functionalised substituents. Here, we exploited diverse building blocks that had been prepared using a unified synthetic approach developed to yield lead-like scaffolds for CNS drug discovery.⁹ We initially prepared analogues of the amino-quinoline **2** in two steps from the ester¹¹ **5** (Table 1). In each case, the ester **5** was aminolysed¹² with the deprotected analogue of the appropriate racemic amine-containing building

Fig. 1 Fragment-based discovery of a new class of BACE1 inhibitors (ref. 11).

^a School of Chemistry, University of Leeds, Leeds, LS2 9JT, UK.

E-mail: a.s.nelson@leeds.ac.uk

^b Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK

† Electronic supplementary information (ESI) available: Synthetic procedures, compound characterisation, biochemical methods and computational approaches. See DOI: 10.1039/c9md00085b

‡ Scores for six molecular properties (MW; clogP; clogD_{7.4}; pK_a; polar surface area; number of hydrogen bond donors) contribute to the CNS drug-likeness score (maximum MPO score: 6) (ref. 7).

Table 1 Synthesis and evaluation of potential BACE1 inhibitors

Building block	Product (Methods ^a)	NR ¹ R ²	Inhibition at 100 μM	IC ₅₀ (μM) [pIC ₅₀]
6a	2 (A, 98%; B: 83%)		>95%	31 [4.51 ± 0.06]
6b	7 ^b (C, D, A, 21%; B, >99%)		<10%	—
6c	8 ^b (C, D, A, 60%; B, 93%)		<10%	—
6d	9 ^b (C, D, A, 75%; B, 32%)		>95%	55 [4.26 ± 0.01]
6e	10 ^b (D, A, 28%; B, 98%)		>95%	29 [4.54 ± 0.02]
6f	11 ^b (C, D, A, 72%; B, >99%)		<10%	—
6g	12 ^b (E, A, 20%; B, 99%)		<10%	—
6h	13 ^b (D, A, 31%; B, >99%)		<10%	—
6i	14 ^b (E, A, 23%; B, >99%)		67%	84 [4.07 ± 0.01]
6j	15 (A, 56%; B, 93%)		<10%	—
6k	16 (A, 90%; B, 47%)		<10%	—
6l	17 ^b (A, 37%; B, >99%)		<10%	—
6m	18 ^b (A, 43%; B, >99%)		<10%	—

^a Methods: A: TBD, toluene, 75 °C; B: TFA, 75 °C; C: NaOMe, MeOH; D: TFA, CH₂Cl₂; E: H₂, Pd/C, MeOH. TBD, triazabicyclodecene; TFA, trifluoroacetic acid. ^b Prepared as a racemate.

block 6 (see Fig. 2); TFA-induced deprotection then gave the corresponding free aminoquinoline.¹¹ For comparison, the known inhibitor 2 and its analogues 15–18 were also prepared from commercially-available amines.

Inhibition of BACE1 was initially assessed at 100 μ M using a fluorescence-quenching assay¹³ based on the cleavage of a peptide substrate bearing a donor and a quencher at its termini. The dose-dependent activity of compounds that displayed significant inhibition at 100 μ M was subsequently determined. Three compounds, in which the cyclohexylmethyl group had been replaced, had broadly comparable activity to the parent aminoquinoline 2 (IC_{50} : 31 μ M): the analogue 10 (IC_{50} : 29 μ M) in which the secondary amide linkage had been retained, and the tertiary amides 9 (IC_{50} : 55 μ M) and 14 (IC_{50} : 84 μ M). The discovery of tertiary amide inhibitors was interesting because the secondary amide NH of 2 has been shown to form a key hydrogen bond interaction with a glycine residue in the BACE1 active site.¹¹ Notably, simplified analogues of the active compounds were inactive: for example, the secondary amide 18 (with a tetrahydropyran replacing the bicyclic ring system of 10) and the tertiary amide 17 (with a 3-benzyl piperidine replacing the benzyl-substituted bicyclic ring system of 14).

To provide some structural insights into these structure-activity relationships, the aminoquinoline 2 and both enantiomers of 10 and 14 were docked onto BACE1 using GOLD (Fig. 3 and ESI†).¹⁴ The structure of BACE1 in complex with the aminoquinoline fragment 1 (PDB 2OHL) was used as a starting point for these *in silico* studies. Since alternative conformations of Tyr71 have been observed in BACE complexes with different aminoquinoline ligands,¹¹ this residue was allowed to be flexible.

Fig. 2 Building blocks used in this study. The chiral building blocks were racemic.

Fig. 3 Interaction of inhibitors with BACE1. Panel A: Docked pose of the aminoquinoline 2 superimposed on the alternative binding modes determined by X-ray crystallography (magenta and purple; PDB 3RU1). Panel B: Docked pose of (4aS,8aS)-10 (green). Panel C: Docked pose of (4aS,8aS)-14 (green).

Crystallographic studies had previously shown that the aminoquinoline 2 has two binding modes¹¹ in which its cyclohexyl substituent occupies either the P1 (magenta) or the P1' (purple) pocket (Fig. 3, Panel A). The docked pose of 2 (green) was similar to the binding mode in which the P1 pocket was targeted, with a similar orientation of Tyr71 (cyan) as the reported crystal structure (blue). Both enantiomers of 10 and 14 were also docked (see ESI†). For 10, the binding mode is predicted to be broadly similar to 2, with a hydrogen bond maintained between Gly230 and the secondary amide NH in the ligand (Panel B). The tertiary amides 9 and 14 lack the capacity to hydrogen bond with Gly230; however, the benzyl substituent of both enantiomers of 14 is predicted to bind in the same pocket as the cyclohexyl group of 2 (Panel C).

By analogy with the parent inhibitor 2 (Fig. 1), we investigated the addition of an *o*-tolyl group and/or a methyl group

Table 2 Synthesis and evaluation of BACE1 inhibitors

<div style="text-align: center;"> <p> 19; R³=H, R⁴=Me 20; R³=<i>o</i>-tolyl, R⁴=H 21; R³=<i>o</i>-tolyl, R⁴=Me </p> </div>								
Substrate	Building block	Product	Method ^a (yield)	pIC ₅₀	IC ₅₀ (μM)			
		NR ¹ R ²	R ³	R ⁴				
19	6e	22	H	Me	D, A, B (43% ^b)	4.48 ± 0.08	34	
20	6e	23	<i>o</i> -Tolyl	H	D, A, B (60%)	7.11 ± 0.07	0.12	
21	6e	24	<i>o</i> -Tolyl	Me	D, A, B (37% ^b)	7.51 ± 0.06	0.031	
19	6d	25	H	Me	C, D, A, B (29% ^b)	5.43 ± 0.02	3.7	
20	6d	26	<i>o</i> -Tolyl	H	C, D, A, B (7%)	5.21 ± 0.06	6.1	
21	6d	27	<i>o</i> -Tolyl	Me	C, D, A, B (16% ^b)	5.29 ± 0.06	5.1	
19	6i	28	H	Me	E, A, B (18% ^b)	4.47 ± 0.03	34	
20	6i	29	<i>o</i> -Tolyl	H	E, A, B (39%)	5.50 ± 0.03	3.2	
21	6i	30	<i>o</i> -Tolyl	Me	E, A, B (15% ^b)	5.57 ± 0.03	2.7	

^a Methods: A: TBD, toluene, 75 °C; B: TFA, 75 °C; C: NaOMe, MeOH; D: TFA, CH₂Cl₂; E: H₂, Pd/C, MeOH. ^b The use of two racemic reactants resulted in a 50 : 50 mixture of diastereomeric products. TBD, triazabicyclodecene; TFA, trifluoroacetic acid.

to the compounds **9**, **10** and **14** (Table 2). In each case, aminolysis of the appropriate ester (**19**, **20** or **21**) was followed TFA-induced deprotection; compounds prepared from the chiral esters **19** and **21** were obtained as 50 : 50 mixtures of racemic diastereomers. The dose-dependent activity of the resulting nine products was determined.

As with the secondary amide **2**, the addition of an *o*-tolyl group to **10** (IC₅₀: 29 μM) to give **23** (IC₅₀: 120 nM) resulted in a dramatic (~240-fold) improvement in activity. Furthermore, the subsequent addition of a methyl group to **23** (to give **24**; IC₅₀: 31 nM) resulted in a further ~4-fold improvement in potency. The CNS drug-likeness scores⁷ of these two compounds (3.47 for **23** and 3.00 for **24**) were broadly comparable with their cyclohexylmethyl analogues (3.20 for **3** and 3.10 for **4**). It is therefore possible to replace the cyclohexylmethyl substituent with a less lipophilic group (Δclog*P* for each pair: ~1.9) whilst maintaining both potency and CNS drug-likeness.

The inhibitor **24**, in which both an *o*-tolyl group and a methyl group have been incorporated, was docked onto BACE1 (see ESI† for all stereoisomers). The structure of BACE1 in complex with the aminoquinoline fragment **1** (PDB 2OHL) was used as a starting point, with alternative conformations of Tyr71 (cyan) allowed. The docked poses were substantially different to those of its unsubstituted analogue **10** (compare Fig. 4, Panel A and ESI† with Fig. 3, Panel B): the P1' pocket was now predicted to be targeted and the Tyr71 had a different orientation and formed a hydrogen bond with the secondary amide of the ligand. In the crystal structure¹¹

Fig. 4 Complexes of 2-amino-6-*o*-tolylquinoline inhibitors with BACE1 with Tyr71 highlighted (cyan). Panel A: Docked pose of a representative stereoisomer of the ligand **24** [with 2*R* configuration in linker and (4*aS*,8*aS*)-configured building block] Panel B: Co-crystal structure of 3-(2-amino-6-*o*-tolylquinolin-3-yl)-*N*-cyclohexylpropanamide with BACE1 (PDB 3RTN).

of 3-(2-amino-6-*o*-tolylquinolin-3-yl)-*N*-cyclohexylpropanamide in complex with BACE1 (PDB 3RTN), the cyclohexyl substituent also targeted the P1' pocket and Tyr71 had a similar orientation (Fig. 4, Panel B).

With the tertiary amides **9** (IC₅₀: 55 µM) and **14** (IC₅₀: 84 µM), the addition of an *o*-tolyl group had a much less dramatic effect: ~8-fold (to give **26**; IC₅₀: 6.1 µM) and ~14-fold (to give **29**; IC₅₀: 3.2 µM) improvements in activity respectively were observed. In addition, the subsequent addition of a methyl groups to **26** and **29** (to give **27** and **30**) resulted in only modest improvements in activity.

Conclusion

We have demonstrated that structurally-diverse, sp³-rich building blocks that were prepared using a unified lead-oriented approach can significantly enrich structure–activity relationships. In particular, we showed that the cyclohexylmethyl group in a series of known BACE1 inhibitors could be replaced productively with alternative structurally-diverse ring systems. Notably, the incorporation of simplified analogues of these alternative ring systems was not productive, and did not yield active BACE1 inhibitors. The availability of diverse building blocks *via* a lead-oriented synthetic approach therefore enabled the replacement of a lipophilic substituent with maintenance of both potency and CNS drug-likeness. The exploitation of diverse building blocks with controlled molecular properties within drug discovery programmes thus may significantly expand opportunities in lead discovery and optimisation.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank Takeda, the University of Leeds and EPSRC (EP/N025652/1) for funding, and Will Farnaby for helpful discussions.

Notes and references

- 1 C. A. Lipinski, *Drug Discovery Today*, 2004, 1, 337.
- 2 (a) A. H. Lipkus, Q. Yuan, K. A. Lucas, S. A. Funk, W. F. Bartelt III, R. J. Schenck and A. J. Trippe, *J. Org. Chem.*, 2008, 73, 4443; (b) M. Garcia-Castro, S. Zimmermann, M. G. Sankar and K. Kumar, *Angew. Chem., Int. Ed.*, 2016, 55, 7586.
- 3 (a) G. W. Bemis and M. A. Murcko, *J. Med. Chem.*, 1996, 39, 2887; (b) S. R. Langdon, N. Brown and J. Blagg, *J. Chem. Inf. Model.*, 2011, 51, 2174.
- 4 (a) F. Lovering, J. Bikker and C. Humblet, *J. Med. Chem.*, 2009, 52, 6752; (b) T. J. Ritchie and S. J. F. Macdonald, *Drug Discovery Today*, 2009, 14, 1011; (c) W. P. Walters, J. Green, J. R. Weiss and M. A. Murcko, *J. Med. Chem.*, 2011, 54, 6405.
- 5 (a) S. J. Teague, A. M. Davis, P. D. Leeson and T. Oprea, *Angew. Chem., Int. Ed.*, 1999, 38, 3743; (b) A. Nadin, C. Hattotuwigama and I. Churcher, *Angew. Chem., Int. Ed.*, 2012, 51, 1114; (c) T. I. Oprea, A. M. Davis, S. J. Teague and P. D. Leeson, *J. Chem. Inf. Comput. Sci.*, 2001, 41, 1308.
- 6 A. K. Ghose, T. Herbertz, R. L. Hudkins, B. D. Dorsey and J. P. Mallamo, *ACS Chem. Neurosci.*, 2012, 3, 50.
- 7 T. T. Wager, X. Hou, P. R. Verhoest and A. Villalobos, *ACS Chem. Neurosci.*, 2010, 1, 435.
- 8 J. Mayol-Llinàs, A. Nelson, W. Farnaby and A. Ayscough, *Drug Discovery Today*, 2017, 22, 965.
- 9 J. Mayol-Llinàs, W. Farnaby and A. Nelson, *Chem. Commun.*, 2017, 53, 12345.
- 10 A. K. Ghosh and H. L. Osswald, *Chem. Soc. Rev.*, 2014, 43, 6765.
- 11 Y. Cheng, T. C. Judd, M. D. Bartberger, J. Brown, K. Chen, R. T. Freneau, Jr., D. Hickman, S. A. Hitchcock, B. Jordan, V. Li, P. Lopez, S. W. Louie, Y. Luo, K. Michelsen, T. Nixey, T. S. Powers, C. Rattan, E. A. Sickmier, D. J. St. Jean, Jr., R. C. Wahl, P. H. Wen and S. Wood, *J. Med. Chem.*, 2011, 54, 5836.
- 12 C. Sabot, K. A. Kumar, S. Meunier and C. Mioskowski, *Tetrahedron Lett.*, 2007, 48, 3863.
- 13 T. Zauner, R. Berger-Hoffmann, K. Müller, R. Hoffmann and T. Zuchner, *Anal. Chem.*, 2011, 83, 7356.
- 14 G. Jones, P. Willett, R. C. Glen, A. R. Leach and R. Taylor, *J. Mol. Biol.*, 1997, 267, 727.